Telaprevir or simeprevir-based triple therapy for recurrent hepatitis C virus among living donor liver transplant recipients

Trial Profile

Telaprevir or simeprevir-based triple therapy for recurrent hepatitis C virus among living donor liver transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Simeprevir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top